Galera Therapeutics (GRTX) News Today $0.04 0.00 (-5.29%) As of 02/21/2025 02:07 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period St. Louis-born Galera Therapeutics sidesteps liquidation, acquires New York biotech companyJanuary 2, 2025 | bizjournals.comGalera Therapeutics completes acquisition of Nova PharmaceuticalsDecember 31, 2024 | globenewswire.comGalera Therapeutics (OTC:GRTX) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comGalera Therapeutics (OTC:GRTX) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comNewron Pharmaceuticals S.p.A. (NP5.DE)August 18, 2024 | finance.yahoo.comGRTX Galera Therapeutics, Inc.August 16, 2024 | seekingalpha.comGalera Announces Board Approval of Complete Liquidation and DissolutionAugust 14, 2024 | globenewswire.comGalera Therapeutics, Inc. Common Stock (GRTX)July 23, 2024 | nasdaq.comGalera Reports First Quarter 2024 Financial Results and Recent Corporate UpdatesMay 13, 2024 | globenewswire.comGalera Therapeutics: Galera Adopts Limited Duration Stockholder Rights AgreementMay 3, 2024 | finanznachrichten.deGalera Adopts Limited Duration Stockholder Rights AgreementMay 3, 2024 | globenewswire.comGalera Therapeutics Seeks Strategic Alternatives Amid Financial Setbacks and Regulatory ChallengesApril 1, 2024 | msn.comGalera Therapeutics: Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate UpdatesMarch 28, 2024 | finanznachrichten.deGalera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate UpdatesMarch 28, 2024 | globenewswire.comGRTX Apr 2024 0.500 callMarch 16, 2024 | finance.yahoo.comGalera Therapeutics, Inc. (GRTX)March 12, 2024 | nz.finance.yahoo.comGalera Therapeutics, Inc.February 27, 2024 | edition.cnn.comGalera Therapeutics Inc (GRTX)February 4, 2024 | investing.comGalera Therapeutics Stock (NASDAQ:GRTX) Dividends: History, Yield and DatesFebruary 4, 2024 | benzinga.comGalera Therapeutics Insiders Lose Out As Stock Sinks To US$0.17January 21, 2024 | finance.yahoo.comLocal publicly traded stocks lag far behind national indices in 2023January 16, 2024 | bizjournals.comDow Tumbles Over 200 Points; US Trade Gap Narrows In NovemberJanuary 9, 2024 | msn.comGalera Therapeutics (GRTX) Price Target Increased by 7.14% to 0.38November 28, 2023 | msn.comGalera Therapeutics: Galera Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNovember 14, 2023 | finanznachrichten.deGalera Therapeutics: Q3 Earnings InsightsNovember 14, 2023 | benzinga.comGalera Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNovember 14, 2023 | finance.yahoo.comGalera Therapeutics's Earnings OutlookNovember 13, 2023 | benzinga.comUS Stocks Fall; Pfizer Swings To Q3 LossNovember 1, 2023 | benzinga.comDow Gains 50 Points; Global Payments Posts Upbeat EarningsOctober 31, 2023 | benzinga.comGalera Therapeutics warns of potential shutdown as it halts clinical trials and stock tanksOctober 31, 2023 | bizjournals.comWhy Is Cancer Focused Galera Therapeutics Stock Sinking Today?October 31, 2023 | msn.comGalera plunges after citing risks to business continuityOctober 31, 2023 | msn.comGalera Therapeutics: Galera Announces Receipt of Type A Meeting Minutes and Strategic UpdateOctober 31, 2023 | finanznachrichten.deGalera Announces Receipt of Type A Meeting Minutes and Strategic UpdateOctober 31, 2023 | finance.yahoo.comTrading was temporarily halted for "GRTX" at 06:10 AM with a stated reason of "News pending."October 31, 2023 | marketbeat.comGalera Therapeutics (GRTX) Gets a Hold from H.C. WainwrightSeptember 19, 2023 | markets.businessinsider.comGalera Schedules Type A Meeting with FDA to Discuss Next Steps for AvasopasemSeptember 18, 2023 | finance.yahoo.comGalera to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 5, 2023 | finance.yahoo.comCiti Sticks to Its Hold Rating for Galera Therapeutics (GRTX)August 30, 2023 | markets.businessinsider.comCitigroup Maintains Galera Therapeutics (GRTX) Neutral RecommendationAugust 30, 2023 | nasdaq.comExpert Ratings for Galera TherapeuticsAugust 29, 2023 | markets.businessinsider.comH.C. Wainwright downgrades Galera Therapeutics (GRTX) to a HoldAugust 16, 2023 | markets.businessinsider.comGalera Reports Second Quarter 2023 Financial Results and Recent Corporate UpdatesAugust 14, 2023 | finance.yahoo.comGalera cut to Underperform at BofA after FDA snub for lead assetAugust 11, 2023 | msn.comWhy Is Galera Therapeutics Stock Sinking Today?August 10, 2023 | msn.comGalera shares plunge 85% on FDA rejection; workforce cut by more than halfAugust 10, 2023 | finance.yahoo.comGalera Therapeutics: Galera Receives Complete Response Letter from U.S. FDA for Avasopasem ManganeseAugust 10, 2023 | finanznachrichten.deGalera Gets CRL From FDA For Avasopasem Manganese, To Cut 70% Jobs; Stock Down In PremarketAugust 10, 2023 | markets.businessinsider.comFDA rejects Galera's treatment for mouth sores in cancer patients, stock -83% after hoursAugust 9, 2023 | msn.comGalera Receives Complete Response Letter from U.S. FDA for Avasopasem ManganeseAugust 9, 2023 | finance.yahoo.com Get Galera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address GRTX Media Mentions By Week GRTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GRTX News Sentiment▼0.000.60▲Average Medical News Sentiment GRTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GRTX Articles This Week▼00▲GRTX Articles Average Week Get Galera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AYTU News Today CYCN News Today CELZ News Today AIM News Today INDP News Today NLSP News Today CNSP News Today ADXN News Today APLM News Today HOTH News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GRTX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRTX Stock Alerts